Tumor cells may circulate in medullary thyroid cancer patients independently of serum calcitonin

in Endocrine-Related Cancer
Correspondence should be addressed to L Willems: luc.willems@uliege.be
Restricted access

Downloadable materials

  • Supplementary Figure 1
  • Supplementary Figure 2
  • Supplementary Figure 3
  • Supplementary Figure 4
  • Supplemental Materials


      Society for Endocrinology

Related Articles

Article Information


All Time Past Year Past 30 Days
Abstract Views 321 321 25
Full Text Views 991 991 0
PDF Downloads 56 56 0



  • View in gallery

    (A) Representative results of CTCs identified using the CellSearch system (Veridex). CTCs were isolated with an EpCAM antibody and labeled for cytokeratin (CK), nuclei (DAPI) and leukocyte common antigen (CD45) as described in the Supplementary data. (B) Summary of CTC counts in thyroid cancer, small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). The numbers and percentages of patients without CTC (0), with one or with more than one are indicated. (C) The TT cell line derived from medullary thyroid carcinoma was labeled with SP17 anti-calcitonin antibody and visualized by fluorescence microscopy. (D) CTCs were isolated by size of epithelial tumor cells (ScreenCell device) from peripheral blood of a patient with medullary thyroid cancer. Cells were labeled and visualized as described in panel B. Arrows indicate calcitonin-positive CTCs (green) and their nuclei (DAPI in blue). (E) The number of calcitonin-positive CTCs was plotted against the concentration of serum calcitonin (pg/mL). R2 is the correlation coefficient.


Google Scholar